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Despite advances in characterizing genetic influences on addiction liability and treatment response, clinical applications
of these efforts have been slow to evolve. Although challenges to clinical translation remain, stakeholders already face
decisions about evidentiary thresholds for the uptake of pharmacogenetic tests in practice. There is optimism about
potential pharmacogenetic applications for the treatment of alcohol use disorders, with particular interest in the OPRM1
A118G polymorphism as a moderator of naltrexone response. Findings from human and animal studies suggest
preliminary evidence for the clinical validity of this association; on this basis, arguments for clinical implementation
can be made in accordance with existing frameworks for the uptake of genomic applications. However, generating
evidence-based guidelines requires evaluating the clinical utility of pharmacogenetic tests. This goal will remain
challenging, largely due to minimal data to inform clinical utility estimates. The pace of genomic discovery highlights
the need for clinical utility and implementation research to inform future translation efforts. Near-term implementation
of promising pharmacogenetic tests can help expedite this goal, generating an evidence base to enable efficient
translation as additional gene-drug associations are discovered.
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Asn40Asp, rs1799971Introduction
Initial optimism about the prospect of genomic medicine
has given way to the realization that clinical applications
will be challenging to identify and implement [1,2]. Ef-
forts to predict disease incidence or severity based on
common genetic variants have shown limited success
[1], raising questions about the utility of genomic appli-
cations in assessing risk for common health conditions.
However, advances in pharmacogenetics have already led
to treatment innovations in tertiary care contexts. The
U.S. Food and Drug Administration currently lists phar-
macogenetic content in >100 drug labels [3]. Genetic
testing is standard for some therapies, and evidence for
potentially actionable pharmacogenetic variants is accu-
mulating quickly [4,5].Correspondence: christian.hendershot@utoronto.ca
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also faces numerous challenges [6-10]. One challenge
is that the rapid pace of genomic sciences has left little
time to apply and evaluate emergent knowledge in clin-
ical contexts [10-12], resulting in a translational research
gap [12,13]. This evidence gap is consistent with the
observation that funding initiatives place heavy priority
on genomic discovery (T1) research, with a compara-
tively minute focus on translational (T2–T4) research
[6,12]. Further complicating translation efforts are nu-
merous challenges inherent to the clinical implemen-
tation of pharmacogenetic tests. At minimum, these
challenges include establishing the clinical validity and
clinical utility of candidate biomarkers; training health
care providers in their application; addressing ethical,
legal, and social implications of genetic testing; navigat-
ing third-party reimbursement issues; and updating
bioinformatics resources to accommodate genomic in-
formation [7-9,14-16].Ltd. This is an Open Access article distributed under the terms of the Creative
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cessary to justify the adoption of promising pharmacoge-
netic tests in practice [6,7,9,17,18]. Perspectives on this
question will differ across disciplines and clinical scenar-
ios, suggesting the need to navigate this issue as it relates
to addiction therapeutics. Because most interventions for
alcohol use disorders have only moderate efficacy, identi-
fying prognostic markers of treatment response is a topic
of significant interest [19-22]. However, existing research
has focused predominantly on the identification or repli-
cation of gene–drug response associations, with little dis-
cussion about preconditions for clinical implementation.
This paper provides a brief discussion of considerations
for implementation, emphasizing the need for near-term
translation research to inform the clinical utility of phar-
macogenetic protocols in alcohol treatment contexts. As
a case scenario, evidence for the OPRM1 A118G poly-
morphism as a moderator of naltrexone response is
discussed. However, these considerations will be relevant
for other gene–drug response associations under study in
the context of alcohol treatments, summaries of which are
provided elsewhere [23-25].
Evidence for genetic moderation of naltrexone response
Naltrexone is an opioid receptor antagonist and front-
line therapy for alcohol dependence. A widely studied
single nucleotide polymorphism in exon 1 of the μ-opioid
receptor gene (OPRM1 A118G, rs1799971) is generally
considered the most promising genetic moderator of
alcohol treatment outcomes [21,22]. Although molecular
evidence concerning the functional role of A118G is not
conclusive [24,26,27], preclinical and human research im-
plies functional relevance of OPRM1 for phenotypes re-
lated to pain and analgesia, stress response, and response
to psychoactive drugs [26]. Of particular clinical relevance
are findings that alcohol-dependent participants with the
minor (118G) allele show relatively better clinical out-
comes (e.g., lower rates of relapse to heavy drinking)
during treatment with naltrexone, but not placebo, com-
pared to those homozygous for the 118A variant (for re-
view see 19,24,26,27). In weighing this evidence, it is
important to note instances of nonreplication [28] and
the lack of large-scale prospective trials [29]. Nonethe-
less, the first meta-analysis on this topic [30] reached
conclusions consistent with initial promising findings re-
ported by Oslin and others [31,32].
Human laboratory evidence also suggested that OPRM1
A118G moderated naltrexone-related reductions in the
hedonic effects of alcohol [33]. This finding is notable in
that stimulant effects of alcohol relate to the risk for heavy
drinking [34] and reflect a potential target of naltrexone.
The identification of a functional equivalent to OPRM1
A118G in rhesus monkeys (C77G) has also allowed inves-
tigations in primate models [35-37]. Primates with the77G variant (which is considered analogous to 118G)
showed higher levels of alcohol preference and self-
administration, and naltrexone preferentially reduced alco-
hol self-administration in these animals [35,37], providing
evidence for cross-species convergence of this finding
[19,35]. Therefore, while the association of OPRM1 with
alcohol use disorder etiology remains controversial [26],
findings suggest the relevance of OPRM1 for a phenotype
of clinical interest: reduction in alcohol consumption dur-
ing treatment with naltrexone versus placebo [19,35].
Overall, these findings offer preliminary evidence for the
clinical validity of OPRM1 A118G as a marker of thera-
peutic response.
Defining sufficient conditions for clinical implementation
A much-debated issue concerns the degree of evidence
necessary to incorporate a promising pharmacogenetic
test in practice. This topic has received limited public
discussion in the alcohol field, despite that decision-
making frameworks for determining the uptake of gen-
omic applications are available. For example, the Centers
for Disease Control and Prevention (CDC) endorses the
ACCE model [38] for evaluating candidate genomic tests
for readiness in practice settings. ACCE emphasizes
three performance aspects of genetic tests: analytic val-
idity (availability of a reliable laboratory assay for the
genetic variant), clinical validity (prognostic value in re-
lation to clinical phenotypes or intermediate phenotypes
of interest), and clinical utility (net benefits minus harms
of implementing the test in practice). A fourth category
addresses ethical, legal and social implications of imple-
menting the genetic test in a specific clinical scenario.
The ACCE model includes 44 standard questions to
guide evidence-based evaluation, although adaptations
have also been made [39]. Example questions are pre-
sented in Table 1.
Analytic validity should not pose a concern in the
OPRM1-naltrexone scenario, since A118G is a single-
point mutation and identifiable with commercial assays.
As for clinical validity, the evidence for OPRM1 is by no
means conclusive, however, initial findings could be con-
sidered promising. Importantly, the ACCE model and
similar frameworks do not require conclusive evidence
from high-quality randomized trials to evaluate clinical
validity. More limited sources of evidence (for example,
nonrandomized studies of acceptable quality, systematic
reviews of lower-quality studies, or meta-analyses with
evidence of heterogeneity) can be considered [5]. In the
case of OPRM1, the existence of several retrospective
trials and subsequent meta-analyses [30,40] is likely suf-
ficient for initial evaluations of clinical validity.
Assuming an encouraging clinical validity profile, im-
plementation decisions will hinge largely on clinical utility,
defined broadly as the net effect (benefits minus harms) of
Table 1 Relevant issues for implementation of genetic tests under the ACCE framework [38]
ACCE element Primary considerations Example questions
Analytic Validity Test reliability/precision. Are test results reliable within and across laboratory settings?
Clinical Validity Genotype-phenotype associations; test sensitivity/specificity
and positive/negative predictive value in relation to clinical
outcomes; population differences; environmental modifiers.
Do clinically relevant outcomes of pharmacotherapy vary
based on genotype in prospective analyses? Do these
findings replicate across populations or clinical settings?
Clinical Utility Net cost-benefit profile of testing. Considerations include
the usefulness of the test for clinical decisions; any impact
of the testing process on patient care; financial costs of
testing; economic consequences of health care decisions
resulting from testing; facility, personal, and educational
requirements associated with testing; informed consent
requirements; and clinical risks associated with testing.
What are the net benefits or harms of testing? In which
treatment settings are genetic tests feasible or acceptable?
Are effective treatment alternatives available under various
test result scenarios? How are pharmacogenetic tests best
implemented in the clinic? Does genetic testing itself
influence patient or provider behaviors?
Ethical, Legal, and Social
Implications
Privacy issues; potential for stigmatization; legal and
reporting issues; safeguards to protect against legal
or ethical infringements.
Could implementation lead to inequities (e.g., racial group
disparities in treatment access)? Would test results potentially
disclose sensitive information about other health outcomes?
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include relevant treatment endpoints (e.g., relapse to heavy
drinking), as well as side effects, adverse events, metabol-
ism profiles, or important intermediate phenotypes. End-
points that can be linked to broader health or economic
metrics (e.g., morbidity/mortality, quality-adjusted life-
years, treatment costs) are seen as particularly important
for determining clinical utility. However, demonstrating
that genotype-based treatment protocols improve these
outcomes is not necessarily sufficient, because numerous
other factors will influence clinical utility in a given con-
text [42]. As one example, a pharmacogenetic protocol
that improves clinical outcomes under efficacy scenarios
could have zero clinical utility without adequate uptake of
the genetic test and/or medication by providers. Similarly,
improved treatment endpoints or distal health outcomes
do not serve as the only indicators of clinical utility [41].
Proximal or “soft” clinical outcomes can be important in
genetic testing scenarios [42]; for instance, personalized
treatment protocols could influence treatment motivation,
perceived quality of care, and adherence to treatment regi-
mens [42,43]. Also, perceived utility of a genetic test for
therapeutic choice could influence uptake of the test or
related medications by providers [41,42]. Ethical, psycho-
social, and legal implications of genetic testing are also im-
portant for informing clinical utility [41,44]. Importantly,
numerous parameters of clinical utility exist and most are
context-dependent, potentially varying based on the clin-
ical syndrome, population, treatment setting, and other
contextual factors [7,39,41].
A major barrier to the clinical translation of pharma-
cogenetics is the shortfall of data to inform estimates of
clinical utility, contributing to the so-called “evidence
dilemma” in genomic medicine [6,45]. This gap exists
primarily at the T2 stage, such that even the most prom-
ising applications are rarely subjected to rigorous research
to inform clinical utility profiles and implementation ques-
tions [6,12,46]. A consequence of this “T2 bottleneck” isthat decisions about clinical implementation must be
made absent comprehensive evidence for or against clin-
ical utility—or else deferred indefinitely [6]. With few ex-
ceptions [47], very little data is available to inform
clinical utility estimates for genetic applications in alco-
hol treatment settings, although somewhat more pro-
gress has been made in the area of nicotine addiction
[10,15,48-53]. Given this evidence shortfall, initial clinical
recommendations for pharmacogenetic tests must be
made without sufficient evidence for or against clinical
utility—a scenario common to most of medicine [6,54].
Addressing implementation in the context of limited
evidence
Most genetic tests are not federally regulated, leaving
stakeholders (e.g., the scientific community, clinicians,
third-party payers) to navigate implementation decisions
[42], usually in the context of insufficient evidence [54].
To facilitate evidence-based recommendations, the CDC
sponsored the Evaluation of Genomic Applications in
Practice and Prevention (EGAPP) initiative. The chief
aim of EGAPP is to develop and test guidelines for the
systematic evaluation of candidate genomic applications
[5]. Candidate applications are subjected to evidence-
based review by an expert panel, following the ACCE
framework and resulting in published recommendations
[55]. The CDC endorses a three-tier evidentiary frame-
work for assessing candidate genomic applications [54,56].
Tier 1 denotes applications with sufficient evidence to rec-
ommend clinical use (e.g., BRCA testing in the context of
family risk for breast and ovarian cancer). Evidence suffi-
cient to discourage clinical use of a test results in assign-
ment to Tier 3. Tier 2 is used for applications with
promising evidence for clinical validity, but insufficient
evidence to recommend for or against clinical adoption—
often reflecting limited data on clinical utility. The vast
majority of pharmacogenetic applications will fall under
Tier 2 [54]. Other Tier 2 examples include genetic risk
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evidence for clinical utility (e.g., assessing family history
during depression screening in primary care). The Clinical
Pharmacogenetic Implementation Consortium (CPIC)
and other expert groups have endorsed similar three-tier
models for evaluating genomic applications [4,57].
The three-tier scheme is noteworthy in that it accom-
modates clinical implementation in the absence of suffi-
cient evidence for or against clinical utility [54,57]. To
aid these decisions, Tier 2 biomarkers can be further
triaged based on anticipated risk-benefit profiles. For ex-
ample, Tier 2 tests with unfavorable risk-benefit profiles
can be subcategorized with a recommendation of “do
not use,” whereas those with neutral or marginally favor-
able profiles may receive recommendations such as
“consider use in clinical practice” or “use with evidence-
based development” [54,57]. Importantly, the latter des-
ignations can justify clinical implementation in the
absence of comprehensive data on clinical utility. No
evidence-based guidelines for gene–drug combinations
specific to addiction therapeutics have been published by
EGAPP or CPIC. In the absence of formal evidence-based
reviews—which will emerge slowly, given an enormous
number of potential gene–drug associations—stakeholders
will largely be tasked with making initial implementation
decisions. Clinical annotations for candidate pharmacoge-
netic tests [58] and models for evidence-based evaluation
of genomic applications [59] are increasingly available to
guide these decisions.
Noninferiority as a basis for implementation
Placebo-controlled, prospective randomized controlled
trials (RCTs) will remain the gold standard for validating
pharmacogenetic applications. These designs reduce
sources of bias and are necessary for testing genotype-
based treatment algorithms [19,29]. However, predicating
clinical adoption on prospective RCTs alone will mean a
protracted path from discovery to translation [12,60]. An
alternative view is that noninferiority of pharmacogenetic
protocols can be sufficient for initial implementation [60].
From this perspective, tests for which the anticipated risk-
benefit profile is neutral or marginally positive could be
implemented and evaluated in practice settings prior to
establishing clear utility on the basis of RCTs [60]. A non-
inferiority approach is not a universal solution [61] but
can serve several purposes, such as acclimating health care
providers and patients to genetic testing; evaluating and
refining treatment algorithms; optimizing the design of
bioinformatics resources and electronic medical records;
and identifying pragmatic barriers to implementation.
These steps can generate important information to inform
clinical utility profiles and clinical practice protocols [60].
On the other hand, deferring these steps until supportive
data from prospective RCTs accumulates will likely delayclinical translation for those tests that ultimately show ac-
ceptable clinical utility [13,60]. As noted above, a reliance
on traditional RCTs alone is also insufficient because most
trials are not designed to collect comprehensive data on
clinical utility.
Because a noninferiority rationale assumes no foresee-
able net harms, an important ethical consideration is
whether pharmacogenetic protocols could compromise
access to best-practice interventions. Ideal scenarios for
early implementation might include those where a gen-
etic test informs assignment to one of two empirically
supported interventions. For instance, evidence for com-
parable efficacy of naltrexone and cognitive-behavioral
therapy (CBT) for alcohol dependence [62] could justify
genotype-based assignment (e.g., assigning naltrexone
and CBT as the front-line interventions for 118G car-
riers and noncarriers, respectively), other considerations
being equal. However, contextual factors are important
to consider. For instance, the range of available thera-
peutic options will vary across treatment settings. As-
suming noninferiority of a pharmacogenetic protocol and
availability of both naltrexone and CBT, a more liberal evi-
dentiary threshold might be used to base treatment selec-
tion on OPRM1. However, in the hypothetical scenario
that naltrexone is the only evidence-based treatment avail-
able, the evidentiary bar should arguably be higher before
restricting use of naltrexone to 118G carriers.
Developing an evidence base
Drawing from discussions in other disciplines, several
recommendations can be made for near-term efforts to
promote translation research in addiction therapeutics.
A general goal is to evaluate candidate pharmacogenetic
applications with approaches that balance methodo-
logical rigor with clinical applicability [8,13,54]. To meet
this aim, a comprehensive, portfolio-based approach to
translation research has been recommended [8,12]. This
approach includes an emphasis on alternative research
designs (e.g., feasibility studies, pragmatic clinical trials,
adaptive designs, observational studies) that can com-
plement RCTs to generate data on clinical utility and
implementation questions [7-9,57]. Early translation ef-
forts can prioritize the most promising genetic markers
as prototypes, allowing for clinical implementation to
be studied concurrent with (rather than being predi-
cated on) prospective RCTs [12]. One critique of this
approach is its apparent circularity; that is, candidate
tests require initial implementation in order to generate
evidence that can inform broader implementation. In
fact, this observation illustrates the evidence dilemma
in genomic medicine [6]. A proposed solution is that, ra-
ther than dictating a linear progression in the steps from
bench to bedside, translation research proceeds as an on-
going, iterative process, including bidirectional knowledge
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at an early stage [12].
These considerations support an argument for provi-
sional implementation of promising pharmacogenetic
protocols, if and when feasible [60]. Such an approach
assumes neutral or marginally favorable risk-benefit pro-
files for these protocols relative to standard care, as well
as supportive local conditions for implementation. Deter-
mining the ideal implementation conditions in addiction
treatment settings will take additional work, although
some minimal conditions can be inferred (e.g., financial
and administrative support; acceptability of genetic test-
ing by staff and patients; affiliation with a laboratory
that meets necessary regulatory standards; the ability to
educate providers on genetic protocols). Implementing
candidate genetic tests in the context of naturalistic, ob-
servational, pragmatic, or comparative effectiveness trials
can produce data on specific implementation questions,
complementing findings from RCTs to inform clinical
utility [13,54]. Ideally, these efforts can be designed to in-
form specific translation questions, including those rele-
vant to the ACCE criteria. This strategy reflects the
chain-of-evidence approach utilized by EGAPP, such that
various sources of data are seen as relevant to informing
clinical utility [5,57]. The identification of key “early
adopter” sites can help to organize implementation
research [8]. Large-scale biobanking and prospective geno-
typing are commonplace in some hospitals [63,64], offering
particularly good venues. To ensure financial support,
funding streams for translational (T2–T4) pharmacogenet-
ics research in alcohol treatment contexts are likely critical
to these aims.
Preliminary evidence on OPRM1 and naltrexone re-
sponse makes this a logical prototype for near-term
translation research. At the same time, more research is
clearly needed to characterize clinical validity and utility
profiles for OPRM1. For example, assessments of clinical
validity require specific attention to test prognostics
(sensitivity, specificity, positive predictive value, and
negative predictive value) in relation to the clinical end-
point in question [65]. Consensus is needed around the
primary clinical endpoint(s) for such analyses, with par-
ticular attention to what constitutes a “positive” or
“negative” treatment response. Relapse to heavy drinking
has served as a common outcome in retrospective trials
[30], but alternative definitions are likely important [31].
Ideally, these outcomes should be defined a priori and
evaluated in prospective studies [29]. Another question
concerns the most appropriate comparator condition
for sensitivity/specificity estimates [65]. One consider-
ation is that real-world treatment algorithms will not
include placebo, and the lack of a single “gold standard”
intervention for alcohol dependence further complicates
this question. Importantly, clinical validity estimates formost genetic tests will always be imprecise, due to en-
vironmental and contextual moderators specific to a given
setting [65].
Regarding clinical utility, a key question is whether
genotype-based treatment algorithms offer advantages
over standard protocols when implemented in clinical
practice scenarios. Research protocols that compare
genotype-based treatment assignment to conventional
methods are needed to address this question. Adaptive
treatment designs [21] could be an important element of
such studies. In addition to measuring traditional clinical
endpoints, such trials should also evaluate proximal out-
comes (e.g., medication adherence, physician attitudes)
that are ultimately important for informing clinical utility
profiles. As noted, such questions can be addressed using
prototype scenarios, even if the overall evidence for
clinical validity and utility remains limited [43]. As
reviewed above, the use of alternative treatment designs,
including noninferiority studies and observational studies
in naturalistic settings, can also help generate clinical
utility data.
Although ethical issues are potentially less obvious in
pharmacogenetic scenarios relative to other areas of gen-
etic testing [60], research on these issues is needed. Ex-
ample issues include privacy considerations related to
biobanking [44] and whether ancillary health risk infor-
mation could be revealed based on test results [66]. A
particularly important issue is the potential for racial or
ethnic group disparities in access to pharmacogenetic
applications or associated treatments [44,67]. For ex-
ample, the low prevalence of the 118G allele in people of
African descent is one potential explanation for limited
efficacy of naltrexone in this population [22]. However,
using self-reported race as a basis for treatment deci-
sions can have significant ethical and societal implica-
tions, potentially exacerbating disparities in health care
access and health outcomes [44].
A key end goal is the development of evidence-based
guidelines for candidate pharmacogenetic applications.
Published guidelines are seen as critical for promoting
awareness of candidate applications, enhancing their up-
take [4,9,13], and informing third-party reimbursement
[6]. Importantly, the process of guideline development is
largely stakeholder-driven [54,59], meaning that those in
the alcohol research and treatment communities will be
tasked with developing and disseminating these guide-
lines. In the scenario of OPRM1, a decade of research
following the initial report [32] has generated multiple
studies, leading to initial meta-analyses [30,40]. The pub-
lication of upcoming prospective trials (and integration
of these results in meta-analyses) would provide an ideal
time for an updated data synthesis that includes clinical
recommendations. Such a process could follow the for-
mat of the EGAPP reviews [55]. Reflecting the general
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a review is a conclusion of “insufficient evidence” to rec-
ommend using OPRM1 for clinical purposes. The ques-
tion then becomes whether to recommend provisional
implementation, for example, in specific clinical scenar-
ios or for purposes of evidence development. Such a
decision depends on whether the aggregate evidence,
even if limited, is deemed “encouraging” or “discouraging”
overall. Importantly, setting the implementation threshold
either too high or too low can have adverse implications
for future translation efforts [6].
Anticipating barriers
Numerous barriers to the clinical implementation of phar-
macogenetic tests have been outlined [9,10,12,15,44,50].
Research is needed to evaluate how these barriers apply
in alcohol treatment settings, and to identify barriers
unique to these settings. A common critique is the po-
tential for adverse responses to genetic testing, includ-
ing concerns that genetic testing might undermine
behavior change efforts. Importantly, evidence for “genetic
fatalism” is limited overall [68]. Genetic tests could also
have favorable effects on treatment motivation or ad-
herence [43,69,70], and initial evidence suggests accept-
ability of genetic tests among those seeking treatment
for alcohol use disorders [47]. Efforts should be made
to address these concerns empirically, rather than de-
ferring to “genetic exceptionalism” (i.e., treating genetic
tests with greater scrutiny than other diagnostic tools)
[71]. One example of a clear barrier in the OPRM1 sce-
nario is the low utilization of naltrexone in both gen-
eral and specialty settings [72], which ultimately limits
clinical utility. Numerous other barriers to implementa-
tion can be anticipated, some of which will be evident
only as implementation efforts progress [7].
Conclusion
The likelihood that pharmacogenetic protocols will see
common use in alcohol treatment scenarios remains un-
known. However, there is optimism about the potential
for personalized approaches and consensus on the im-
portance of predicting treatment response [19-22,24,67],
giving reason to support near-term clinical translation
research. Ultimately, the potential public health benefits
of pharmacogenetics research are contingent on efficient
translation—in turn requiring greater commitment to
clinical utility and implementation research [12,45].
Stakeholders in the field will be responsible for setting
translational research and funding priorities, navigating
implementation issues, and developing consensus guide-
lines for candidate applications. A clear goal is to gener-
ate much-needed evidence on the clinical utility of such
applications in treatment settings, in turn leading to
evidence-based guidelines for those applications that showthe potential for utility. Near-term evaluation of candi-
date pharmacogenetic protocols in clinical settings can
help expedite this goal, generating an evidence base to
enable efficient translation as additional gene–drug re-
sponse associations are discovered.
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